1,586 Shares in Johnson & Johnson $JNJ Bought by Acorns Advisers LLC

Key Points

• Acorns Advisers LLC acquired 1,586 shares of Johnson & Johnson stock valued at approximately $263,000 in the first quarter, contributing to institutional investors owning 69.55% of the company’s stock.
• Executive Vice President Jennifer L. Taubert sold 56,471 shares at an average price of $177.81, reducing her ownership by 24.08% and bringing her remaining shares to approximately $31.65 million.
• Several brokerages raised their price targets for Johnson & Johnson stock, with a new average target price of $176.29 and a consensus rating of “Moderate Buy” from analysts.

Acorns Advisers LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 1,586 shares of the company's stock, valued at approximately $263,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Highline Wealth Partners LLC boosted its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the first quarter valued at $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth about $48,000. von Borstel & Associates Inc. purchased a new stake in Johnson & Johnson in the 1st quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson in the 1st quarter worth about $52,000. Institutional investors own 69.55% of the company's stock.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on JNJ. Barclays lifted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Morgan Stanley raised their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Guggenheim restated a "neutral" rating and set a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $177.12 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $426.57 billion, a P/E ratio of 18.94, a P/E/G ratio of 2.27 and a beta of 0.40. The business's fifty day moving average is $169.51 and its two-hundred day moving average is $161.02. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.